Piper Sandler keeps an Overweight rating on Leap Therapeutics (LPTX) after BeiGene (BGNE) decided not to exercise its option for the Asian rights to DKN-01. While a "disappointing outcome at first glance," global rights now remain fully with Leap, including potentially the most valuable territories in Asia given the lead first-line indication, the analyst tells investors in a research note. The firm argues that BeiGene’s decision presents the opportunity for Leap to potentially extract more value out of the program.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LPTX:
